{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:13:00Z","timestamp":1791475980206,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T00:00:00Z","timestamp":1410307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40262-014-0179-5","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T13:30:44Z","timestamp":1410269444000},"page":"1161-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Assessment of the Relationship Between Methotrexate Polyglutamates in Red Blood Cells and Clinical Response in Patients Commencing Methotrexate for Rheumatoid Arthritis"],"prefix":"10.1007","volume":"53","author":[{"given":"Shan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Duffull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Dalrymple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Korell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,10]]},"reference":[{"issue":"2","key":"179_CR1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.20167","volume":"50","author":"CM Lambert","year":"2004","unstructured":"Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum. 2004;50(2):364\u201371.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"179_CR2","first-page":"844","volume":"22","author":"P Lafforgue","year":"1995","unstructured":"Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1995;22(5):844\u20139.","journal-title":"J Rheumatol"},{"key":"179_CR3","doi-asserted-by":"crossref","first-page":"978396","DOI":"10.1155\/2012\/978396","volume":"2012","author":"KI Halilova","year":"2012","unstructured":"Halilova KI, Brown EE, Morgan SL, Bridges SL Jr, Hwang MH, Arnett DK, et al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol. 2012;2012:978396\u2013402. doi: 10.1155\/2012\/978396 .","journal-title":"Int J Rheumatol"},{"issue":"10","key":"179_CR4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.biopha.2006.09.007","volume":"60","author":"L Stamp","year":"2006","unstructured":"Stamp L, Roberts R, Kennedy M, Barclay M, O\u2019Donnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis: are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother. 2006;60(10):678\u201387.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"179_CR5","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","volume":"92","author":"BN Cronstein","year":"1993","unstructured":"Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92(6):2675\u201382. doi: 10.1172\/jci116884 .","journal-title":"J Clin Invest"},{"issue":"8","key":"179_CR6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60(8):729\u201335. doi: 10.1136\/ard.60.8.729 .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"179_CR7","first-page":"S95","volume":"63","author":"L Haandel van","year":"2011","unstructured":"van Haandel L, Leeder JS, Becker ML. Measurement of methotrexate metabolites in peripheral blood mononuclear cells in juvenile idiopathic arthritis: a more relevant cellular biomarker for drug response? Arthritis Rheum. 2011;63(10):S95.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"179_CR8","first-page":"313","volume":"17","author":"P Angelis-Stoforidis","year":"1999","unstructured":"Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17(3):313\u201320.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"179_CR9","first-page":"156","volume":"30","author":"EL Hobl","year":"2012","unstructured":"Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Broll H, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol. 2012;30(2):156\u201363.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"179_CR10","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","volume":"50","author":"T Dervieux","year":"2004","unstructured":"Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50(9):2766\u201374. doi: 10.1002\/art.20460 .","journal-title":"Arthritis Rheum"},{"issue":"8","key":"179_CR11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/ard.2004.033399","volume":"64","author":"T Dervieux","year":"2005","unstructured":"Dervieux T, Furst D, Lein D, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64(8):1180\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"179_CR12","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3899\/jrheum.110481","volume":"38","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Barclay ML, O\u2019Donnell JL, Zhang M, Drake J, Frampton C, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2540\u20137.","journal-title":"J Rheumatol"},{"issue":"11","key":"179_CR13","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","volume":"58","author":"JM Dalrymple","year":"2008","unstructured":"Dalrymple JM, Stamp LK, O\u2019Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3299\u2013308.","journal-title":"Arthritis Rheum"},{"key":"179_CR14","unstructured":"Lee YJ, Krishnaswami S, Harnisch L, French J, Park K, editors. Model-based evaluation of DAS28 as a potential surrogate for ACR20 to establish the dose-response relationship for disease modifying anti-rheumatic drugs. A case study using tasocitinib (CP-690,550), an oral JAK inhibitor. http:\/\/www.page-meeting.org\/?abstract=1704 . Population Approach Group in Europe (PAGE); 2012, Berlin."},{"issue":"5 Suppl 39","key":"179_CR15","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"179_CR16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-013-0052-y","volume":"52","author":"J Korell","year":"2013","unstructured":"Korell J, Stamp LK, Barclay ML, Dalrymple JM, Drake J, Zhang M, et al. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clin Pharmacokinet. 2013;52(6):475\u201385.","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"179_CR17","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1016\/S0021-9258(19)81516-8","volume":"263","author":"JR Appleman","year":"1988","unstructured":"Appleman JR, Prendergast N, Delcamp TJ, Freisheim JH, Blakley RL. Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. J Biol Chem. 1988;263(21):10304\u201313.","journal-title":"J Biol Chem"},{"issue":"17","key":"179_CR18","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","volume":"260","author":"CJ Allegra","year":"1985","unstructured":"Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260(17):9720\u20136.","journal-title":"J Biol Chem"},{"issue":"15","key":"179_CR19","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","volume":"82","author":"CJ Allegra","year":"1985","unstructured":"Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA. 1985;82(15):4881\u20135. doi: 10.1073\/pnas.82.15.4881 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"179_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","volume":"71","author":"SB Duffull","year":"2011","unstructured":"Duffull SB, Wright DFB, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses: a clinical viewpoint. Br J Clin Pharmacol. 2011;71(6):807\u201314. doi: 10.1111\/j.1365-2125.2010.03891.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"179_CR21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"LP Zhang","year":"2003","unstructured":"Zhang LP, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387\u2013404. doi: 10.1023\/B:JOPA.0000012998.04442.1f .","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"179_CR22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711\u201326. doi: 10.1007\/s10928-007-9066-0 .","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"179_CR23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.27201","volume":"62","author":"L Stamp","year":"2010","unstructured":"Stamp L, O\u2019Donnell J, Chapman P, Zhang M, James J, Frampton C, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010;62(2):359\u201368. doi: 10.1002\/art.27201 .","journal-title":"Arthritis Rheum"},{"issue":"10","key":"179_CR24","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"T Dervieux","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54(10):3095\u2013103.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"179_CR25","first-page":"203723","volume":"28","author":"M Bulatovic Calasan","year":"2013","unstructured":"Bulatovic Calasan M, den Boer E, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. 2013;28(10):203723.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"179_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43(1):22\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"179_CR27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/03009740600718080","volume":"35","author":"JE Oliver","year":"2006","unstructured":"Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol. 2006;35(3):169\u201374. doi: 10.1080\/03009740600718080 .","journal-title":"Scand J Rheumatol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0179-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0179-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T17:23:26Z","timestamp":1650129806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0179-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,10]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0179-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,10]]}}}